title: [Secondary necrotizing fasciitis associated with panitumumab].
authors.affiliation: Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: nataliade.amuriza@salud.madrid.org.
authors.forename: Natalia
authors.initials: N
authors.lastname: de Amuriza-Chicharro
authors.forename: Cristina
authors.initials: C
authors.lastname: Gastalver-Martín
authors.forename: Susana
authors.initials: S
authors.lastname: Cortijo-Cascajares
authors.forename: José Miguel
authors.initials: JM
authors.lastname: Ferrari-Piquero
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D015984:Causality; D015179:Colorectal Neoplasms / Q000188:drug therapy; D003646:Debridement; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D019115:Fasciitis, Necrotizing / Q000139:chemically induced* / Q000601:surgery; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D000077544:Panitumumab; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D012811:Sigmoid Neoplasms / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D009363:Neoplasm Proteins; D009944:Organoplatinum Compounds; D047428:Protein Kinase Inhibitors; D000077150:Oxaliplatin; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D005472:Fluorouracil